Statins and sepsis: multiple modifications at multiple levels

被引:216
作者
Terblanche, Marius
Almog, Yaniv
Rosenson, Robert
Smith, Terry S.
Hackam, Daniel G.
机构
[1] St Thomas Hosp, Dept Crit Care Med, London SE1 7EH, England
[2] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada
[3] Sunnybrook Hlth Sci Ctr, Div Clin Pharmacol & Toxicol, Toronto, ON M4N 3M5, Canada
[4] Ben Gurion Univ Negev, Soroka Med Ctr, Med Intens Care Unit, IL-84105 Beer Sheva, Israel
[5] Univ Michigan, Dept Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA
[6] Inst Clin Evaluat Sci, Toronto, ON, Canada
关键词
D O I
10.1016/S1473-3099(07)70111-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Sepsis, an infection-induced inflammatory syndrome, is a leading and increasing cause of mortality worldwide. Animal and human observational studies suggest statins may prevent the morbidity and mortality associated with the sepsis syndrome. In this Review, we describe the demonstrated mechanisms through which statins modulate the inflammatory response associated with sepsis. These mechanisms include effects on cell signalling with consequent changes at the transcriptional level, the induction of haem oxygenase, the direct alteration of leucocyte-endothelial cell interaction, and the reduced expression of MHC II. Since statins do not target individual inflammatory mediators, but possibly reduce the overall magnitude of the systemic response, this effect could prove an important distinguishing feature modulating the host response to septic insults. This work establishes the biological plausibility needed for future trials of statins in critical illness.
引用
收藏
页码:358 / 368
页数:11
相关论文
共 114 条
[1]   Akt/protein kinase B [J].
Abraham, E .
CRITICAL CARE MEDICINE, 2005, 33 (12) :S420-S422
[2]   Statins, inflammation, and sepsis - Hypothesis [J].
Almog, Y .
CHEST, 2003, 124 (02) :740-743
[3]   The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases [J].
Almog, Yaniv ;
Novack, Victor ;
Eisinger, Miruna ;
Porath, Avi ;
Novack, Lena ;
Gilutz, Harel .
CRITICAL CARE MEDICINE, 2007, 35 (02) :372-378
[4]  
ANDERSON RN, 2001, NATL VITAL STAT REP, V52, P1
[5]  
Ando H, 2000, J PHARMACOL EXP THER, V294, P1043
[6]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[7]   NADPH oxidase: An update [J].
Babior, BM .
BLOOD, 1999, 93 (05) :1464-1476
[8]   Bench-to-bedside review: Microvascular dysfunction in sepsis - hemodynamics, oxygen transport, and nitric oxide [J].
Bateman, RM ;
Sharpe, MD ;
Ellis, CG .
CRITICAL CARE, 2003, 7 (05) :359-373
[9]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[10]   Role of NF kappa B in the mortality of sepsis [J].
Bohrer, H ;
Qiu, F ;
Zimmerman, T ;
Zhang, YM ;
Jllmer, T ;
Mannel, D ;
Bottiger, BW ;
Stern, DM ;
Waldherr, R ;
Saeger, HD ;
Ziegler, R ;
Bierhaus, A ;
Martin, E ;
Nawroth, PP .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (05) :972-985